Evidence map›Paper›PMID 34665232›Full record

ArticleTranslational vision science & technology2021

Demographic, Comorbid, and Clinical Variables Associated With Pointwise Visual Field Damage in Glaucoma: Data From the AGIS and CIGTS Clinical Trials.

Brenda W Gillespie, Leslie M Niziol, Joshua R Ehrlich, Chris A Johnson, Joseph Caprioli, Paul C VanVeldhuisen, Paul R Lichter, David C Musch

Open access · goldAbstract read
In one paragraph

Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Brenda W GillespieDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Leslie M NiziolDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, USA.
Joshua R EhrlichDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, USA.
Chris A JohnsonDepartment of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA.
Joseph CaprioliStein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Paul C VanVeldhuisenThe Emmes Company, LLC, Rockville, MD, USA.
Paul R LichterDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, USA.
David C MuschDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · USEmmes (United States) · USUniversity of California, Los Angeles · USUniversity of Iowa · US

Funding

Glaucoma progression ? Modeling its trajectory and contributing factors: evidence from AGIS and CIGTSR21EY028997 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUSCH, DAVID C · 2018 to 2019
$442k
NEI NIH HHS R21 EY028997
6 · The paper itself

Abstract

Purpose: To investigate differences across the visual field (VF) in the rate of glaucomatous progression, the likelihood of defect in four disease severity cross-sections, and comparisons of subgroups in each of between 12 demographic, comorbid, and clinical variables. Methods: Two long-term glaucoma clinical trials used Humphrey Field Analyzer 24-2 VFs to calculate pointwise deviations from age-matched normal controls. Slopes of glaucomatous progression over time were calculated per participant using linear mixed models. Pointwise differences between subgroups in slopes and cross-sectional categories were tested, adjusting for multiple comparisons using false discovery rate (FDR) and Q values. Results: Pointwise data were available for 1118 patients who had 15,073 VFs. On average, defects were seen at all VF points. Of the 12 variables, six had average pointwise slopes where Subgroup 1 had significantly faster progression than Subgroup 2 at all or many of the 52 VF points: participants who were older (≥65 vs. younger), 52/52; were male, 13/52; had diabetes, 29/52; had hypertension, 46/52; had a larger cup-to-disc ratio (≥0.7), 36/52; or had larger differences in absolute mean deviation (MD) between eyes (>3 dB), 52/52. Cross-sectional patterns at MD severity of -12 to -6.1 dB showed strong midline effects for gender and other patterns for hypertension, cup-to-disc ratio, absolute difference in MD between eyes, and disc notching. Conclusions: The approach used provides new longitudinal and cross-sectional insights into variation across the VF associated with demographic, comorbid, and clinical variables. Translational Relevance: This exploration and characterization of variable effects in the setting of pointwise VF testing may enable clinicians to anticipate patterns of VF loss based on demographic, comorbid, and clinical associations.

Indexed as

GlaucomaVisual FieldsCross-Sectional StudiesDemographyDisease ProgressionHumansIntraocular PressureMaleRetrospective Studies

Identifiers

PMID34665232
PMCPMC8543401
OpenAlexW3205953377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.